我們已在上線！進一步了解

Clover Health Investments

CLOV

市值 US$23.8億

4.48 USD

-0.20

4.27%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

4.50

+0.02

0.45%

1天

-4.27%

5天

-6.28%

1個月

-1.75%

3個月

1.82%

6個月

107.41%

今年迄今

85.89%

1年

65.93%

5年

-43.22%

10年

-56.08%

關於： Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

員工： 724

醫療保健健康保險計畫

新聞

正面

中性

負面

市場情緒 3個月

正面 33.3%

中性 61.1%

負面 5.6%

Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027

WILMINGTON, Del., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare & Medicaid Services (“CMS”) has awarded its PPO Medicare Advantage (“MA”) plans a rating of 5 Stars and its HMO MA plan a rating of 4.5 Stars for 2027, which will affect payment year 2028.

Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027

Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026

WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, November 4, 2026.

Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026

Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

WILMINGTON, Del., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its 2027 Medicare Advantage (MA) plan offerings, with a continued focus on PPO choice, affordable access to preventive care and meaningful member value.

Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.

WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.

UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.

Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.

WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.

Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.

Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens

Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.

Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens

Clover Health to Participate in Upcoming Investor Conferences

WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.

Clover Health to Participate in Upcoming Investor Conferences

Clover Health Is A 'Buy' Because Of Its AI

Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.

Clover Health Is A 'Buy' Because Of Its AI

Clover Health Investments: Real Turnaround, But Already Priced In

Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.

Clover Health Investments: Real Turnaround, But Already Priced In

Clover Health Is Proving Its Profit Model

Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.

Clover Health Is Proving Its Profit Model

查看新聞排名

價格圖表採用Lightweight Charts™實作